Akili Interactive

Akili Interactive is a pioneering digital therapeutics (DTx) company that builds clinically validated cognitive treatments delivered entirely through high-quality video game experiences. Instead of using traditional pharmaceutical mechanisms, Akili targets cognitive deficiencies at their source in the brain. Its proprietary therapeutic engine utilizes specific sensory stimuli and motor challenges designed to engage and train the fronto-parietal cortex—the area of the brain responsible for executive function and attentional control. This approach creates a new category of medicine that possesses the clinical rigor of a medical device but is experienced as adaptive, immersive entertainment.

Following commercial challenges surrounding insurance reimbursement for prescription digital therapeutics, Akili executed a strategic pivot toward an over-the-counter, direct-to-consumer model. To achieve sustainable scale, Akili completed a go-private merger with Virtual Therapeutics. Under this unified framework, Akili operates as a wholly owned subsidiary, combining its mobile digital therapeutics expertise with Virtual Therapeutics’ robust portfolio of virtual reality (VR) mental health solutions and gaming infrastructure to address global behavioral health needs at scale.

Akili pairs its therapeutic video games with dedicated companion software to streamline data tracking and clinical visibility. Parents and adult users utilize the EndeavorRx Insight® app, which tracks daily treatment compliance, monitors in-game progress, and visualizes behavioral changes over time using standardized check-ins. For healthcare providers, the data can be synthesized into structured progress summaries that inform clinical consultations. This integrated loop helps care teams track treatment adherence and easily determine how digital interventions are impacting a patient's executive functioning alongside traditional care plans.

The company’s flagship product line is built around its proprietary Selective Stimulus Management Engine (SSME) technology, primarily focused on Attention-Deficit/Hyperactivity Disorder (ADHD):

EndeavorRx®: The first FDA-cleared and CE-marked prescription video game treatment intended to improve attention function in pediatric patients (ages 8 to 17) with primarily inattentive or combined-type ADHD.

EndeavorOTC®: A clinically validated, over-the-counter version designed explicitly for adults (ages 18 and older) to improve focus, concentration, and daily multi-tasking capabilities.
In clinical trials, these non-stimulant digital therapies demonstrated statistically significant, measurable improvements in objective attention metrics and broader daily operational behaviors.